Urate-induced epigenetic modifications in myeloid cells.
Cytokines
DNA methylation
Epigenetics
Gout
Hyperuricemia
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
28 07 2021
28 07 2021
Historique:
received:
22
03
2021
accepted:
12
07
2021
entrez:
29
7
2021
pubmed:
30
7
2021
medline:
14
8
2021
Statut:
epublish
Résumé
Hyperuricemia is a metabolic condition central to gout pathogenesis. Urate exposure primes human monocytes towards a higher capacity to produce and release IL-1β. In this study, we assessed the epigenetic processes associated to urate-mediated hyper-responsiveness. Freshly isolated human peripheral blood mononuclear cells or enriched monocytes were pre-treated with solubilized urate and stimulated with LPS with or without monosodium urate (MSU) crystals. Cytokine production was determined by ELISA. Histone epigenetic marks were assessed by sequencing immunoprecipitated chromatin. Mice were injected intraarticularly with MSU crystals and palmitate after inhibition of uricase and urate administration in the presence or absence of methylthioadenosine. DNA methylation was assessed by methylation array in whole blood of 76 participants with normouricemia or hyperuricemia. High concentrations of urate enhanced the inflammatory response in vitro in human cells and in vivo in mice, and broad-spectrum methylation inhibitors reversed this effect. Assessment of histone 3 lysine 4 trimethylation (H3K4me3) and histone 3 lysine 27 acetylation (H3K27ac) revealed differences in urate-primed monocytes compared to controls. Differentially methylated regions (e.g. HLA-G, IFITM3, PRKAB2) were found in people with hyperuricemia compared to normouricemia in genes relevant for inflammatory cytokine signaling. Urate alters the epigenetic landscape in selected human monocytes or whole blood of people with hyperuricemia compared to normouricemia. Both histone modifications and DNA methylation show differences depending on urate exposure. Subject to replication and validation, epigenetic changes in myeloid cells may be a therapeutic target in gout.
Identifiants
pubmed: 34321071
doi: 10.1186/s13075-021-02580-1
pii: 10.1186/s13075-021-02580-1
pmc: PMC8317351
doi:
Substances chimiques
IFITM3 protein, human
0
Membrane Proteins
0
RNA-Binding Proteins
0
Uric Acid
268B43MJ25
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
202Informations de copyright
© 2021. The Author(s).
Références
Nature. 2003 Oct 2;425(6957):516-21
pubmed: 14520412
Ann Rheum Dis. 2016 Jan;75(1):286-94
pubmed: 25362043
Arthritis Rheum. 2010 Nov;62(11):3237-48
pubmed: 20662061
J Am Soc Nephrol. 2007 May;18(5):1516-24
pubmed: 17409313
Science. 2014 Sep 26;345(6204):1250684
pubmed: 25258083
Cell Host Microbe. 2011 May 19;9(5):355-61
pubmed: 21575907
Nature. 2009 May 7;459(7243):108-12
pubmed: 19295514
J Diabetes Complications. 2014 Mar-Apr;28(2):122-3
pubmed: 24388550
N Z Med J. 2018 Nov 9;131(1485):8-12
pubmed: 30408813
Adv Exp Med Biol. 1993;329:281-6
pubmed: 7691031
Nucleic Acids Res. 2016 Jan 4;44(D1):D710-6
pubmed: 26687719
Circulation. 2016 Aug 23;134(8):611-24
pubmed: 27496857
J Immunol Res. 2016;2016:4326495
pubmed: 27652273
Cell Host Microbe. 2012 Aug 16;12(2):223-32
pubmed: 22901542
Ann Rheum Dis. 2009 Feb;68(2):273-8
pubmed: 18390571
Blood. 2009 Mar 5;113(10):2324-35
pubmed: 19104081
Nat Med. 2016 Aug;22(8):952-60
pubmed: 27376574
Nature. 2006 Mar 9;440(7081):237-41
pubmed: 16407889
Nat Genet. 2019 Oct;51(10):1459-1474
pubmed: 31578528
Commun Biol. 2019 Apr 8;2:115
pubmed: 30993211
J Clin Invest. 1991 Jan;87(1):20-6
pubmed: 1985096
Cell. 2016 Nov 17;167(5):1354-1368.e14
pubmed: 27863248
Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1731-8
pubmed: 24903093
Mol Cell Biol. 2012 Jul;32(14):2837-48
pubmed: 22586267
Science. 2014 Sep 26;345(6204):1251086
pubmed: 25258085
BMC Med. 2017 May 31;15(1):108
pubmed: 28566086
J Am Chem Soc. 1976 Apr 14;98(8):2319-23
pubmed: 1254868
J Immunol. 2014 Jun 15;192(12):6102-10
pubmed: 24795458
Arthritis Rheum. 1991 Feb;34(2):141-5
pubmed: 1994910
Genome Biol. 2016 Oct 7;17(1):208
pubmed: 27717381
Arthritis Rheumatol. 2020 May;72(5):802-814
pubmed: 31738005
PLoS One. 2017 Aug 7;12(8):e0181100
pubmed: 28786993
Proc Natl Acad Sci U S A. 2017 May 23;114(21):5485-5490
pubmed: 28484006
Ann Rheum Dis. 2016 Apr;75(4):755-62
pubmed: 25649144
Ann Rheum Dis. 1995 May;54(5):351-4
pubmed: 7794039
Arthritis Res Ther. 2012 Jul 04;14(4):R158
pubmed: 22762240
Ann Rheum Dis. 2016 Jan;75(1):124-30
pubmed: 25187157
Eur J Immunol. 2014 Dec;44(12):3669-79
pubmed: 25229885
Nat Immunol. 2013 May;14(5):454-60
pubmed: 23502856
J Biol Chem. 2004 Aug 13;279(33):34698-704
pubmed: 15175334
Hum Mol Genet. 2020 Apr 15;29(6):923-943
pubmed: 31985003
BMC Musculoskelet Disord. 2015 Aug 19;16:196
pubmed: 26286027
Lancet. 2016 Oct 22;388(10055):2039-2052
pubmed: 27112094
Clin Vaccine Immunol. 2016 Dec 5;23(12):926-933
pubmed: 27733422
Ageing Res Rev. 2015 Nov;24(Pt A):29-39
pubmed: 25641058
J Immunol Methods. 2003 Jul;278(1-2):283-92
pubmed: 12957415
Biochim Biophys Acta. 2013 Oct;1832(10):1715-22
pubmed: 23665398
Ann Hum Genet. 2015 Nov;79(6):470-80
pubmed: 26420513
J Clin Invest. 2010 Jun;120(6):1939-49
pubmed: 20501947
Nat Genet. 2013 Feb;45(2):145-54
pubmed: 23263486